Literature DB >> 10023836

In vivo evaluation of a closed loop monitoring strategy for induced paralysis.

D Ramakrishna1, K Behbehani, K Klein, J Mokhtar, W W von Maltzahn, R C Eberhart, M Dollar.   

Abstract

OBJECTIVE: Reliable closed loop infusion systems for regulating paralysis level can be a great convenience to the anesthesiologists in automating their task. This paper describes the in vivo performance evaluation of a self-tuning controller that is designed to accommodate large variations in patient drug sensitivity, drug action delays and environmental interfering noise.
METHODS: The infusion system was evaluated in six adult mongrel dogs. Following the manual induction of paralysis by an anesthesiologist, the controller regulated the infusion of vecuronium to maintain a desired level of paralysis. The integrated EMG response of the hypothenar muscle to a train-of-four stimulation of the ulnar nerve quantified the depth of paralysis. The controller's robustness was tested by contaminating the sensed twitch signal with electrocautery noise and electrode disconnection.
RESULTS: The controller reached the initial level of paralysis of 100% in about 4.0 minutes and arrived at the desired level of 90% with an overshoot of 6.38% (+/-6.82). It maintained the desired level of paralysis with a 2.04% (+/-1.20) mean offset at 90% and 0.4% (+/-0.5) mean offset at 80% steady state level, respectively. The mean infusion rate to sustain 90% and 80% paralysis were 2.70 (+/-2.05) and 2.15 (+/-2.57) ((mg/kg)/min), respectively.
CONCLUSIONS: The system adapted to a large variation in the sample subject drug sensitivity. It remained stable despite large amplitude disturbances and maintained the paralysis at the desired level following the removal of the disturbances.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10023836     DOI: 10.1023/a:1009983117847

Source DB:  PubMed          Journal:  J Clin Monit Comput        ISSN: 1387-1307            Impact factor:   2.502


  13 in total

1.  Use of a pharmacokinetic-dynamic model for the automatic feedback control of atracurium.

Authors:  H Schwilden; K T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Adaptive closed-loop feedback control of vecuronium-induced neuromuscular relaxation.

Authors:  K T Olkkola; H Schwilden
Journal:  Eur J Anaesthesiol       Date:  1991-01       Impact factor: 4.330

Review 3.  Neuromuscular transmission and its blockade. Pharmacology, monitoring and physiology updated.

Authors:  R M Jones
Journal:  Anaesthesia       Date:  1985-10       Impact factor: 6.955

4.  A portable self-learning fuzzy logic control system for muscle relaxation.

Authors:  N D Edwards; D G Mason; J J Ross
Journal:  Anaesthesia       Date:  1998-02       Impact factor: 6.955

5.  Performance assessment of an adaptive model-based feedback controller: comparison between atracurium, mivacurium, rocuronium and vecuronium.

Authors:  M Kansanaho; K T Olkkola
Journal:  Int J Clin Monit Comput       Date:  1996-11

6.  Self-learning fuzzy logic control of neuromuscular block.

Authors:  J J Ross; D G Mason; D A Linkens; N D Edwards
Journal:  Br J Anaesth       Date:  1997-04       Impact factor: 9.166

7.  A model-based self-adjusting two-phase controller for vecuronium-induced muscle relaxation during anesthesia.

Authors:  R R Jaklitsch; D R Westenskow
Journal:  IEEE Trans Biomed Eng       Date:  1987-08       Impact factor: 4.538

8.  Infusion of vecuronium controlled by a closed-loop system.

Authors:  J W de Vries; H H Ros; L H Booij
Journal:  Br J Anaesth       Date:  1986-10       Impact factor: 9.166

9.  Accommodation of time delay variations in automatic infusion of sodium nitroprusside.

Authors:  J S Delapasse; K Behbehani; K Tsui; K W Klein
Journal:  IEEE Trans Biomed Eng       Date:  1994-11       Impact factor: 4.538

10.  Self-tuning, microprocessor-based closed-loop control of atracurium-induced neuromuscular blockade.

Authors:  P C Uys; D F Morrell; H S Bradlow; L B Rametti
Journal:  Br J Anaesth       Date:  1988-12       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.